目的 分析復(fù)方皂礬丸治療FOLFOX4方案所致結(jié)直腸癌患者貧血的臨床效果。方法 回顧性選擇2022年1月—2024年6月中國科學(xué)技術(shù)大學(xué)附屬第一醫(yī)院收取的83例結(jié)直腸癌經(jīng)FOLFOX4方案化療后出現(xiàn)貧血的患者。按治療貧血的方法不同將患者分為兩組，對照組（n=41）應(yīng)用重組人促紅素注射液治療；觀察組（n=42）在對照組基礎(chǔ)上采用復(fù)方皂礬丸治療；對比兩組近期效果、不良反應(yīng)、貧血狀況及骨髓造血功能等。結(jié)果 觀察組近期貧血改善效果（85.71%）高于對照組（58.54%），治療前兩組患者中醫(yī)主癥、次癥評分比較差異無統(tǒng)計(jì)學(xué)意義（P＞0.05），而在治療后兩組患者主癥、次癥評分均較本組治療前顯著降低（P＜0.05）；治療后觀察組主癥、次癥評分均顯著低于對照組（P＜0.05）；治療前兩組各項(xiàng)客觀指標(biāo)[前白蛋白（PA）、白蛋白（ALB）、血紅蛋白（Hb）、白細(xì)胞（WBC）、紅細(xì)胞（RBC）、血小板計(jì)數(shù)（PLT）及CD3⁺、CD4⁺、CD4⁺/CD8⁺]比較差異無統(tǒng)計(jì)學(xué)意義（P＞0.05），而在治療后兩組各項(xiàng)客觀指標(biāo)均較本組治療前顯著降低（P＜0.05）；治療后觀察組各項(xiàng)指標(biāo)均顯著高于對照組（P＜0.05）。兩組不良反應(yīng)比較差異不顯著（P＞0.05）。結(jié)論 復(fù)方皂礬丸可改善治療FOLFOX4方案所致結(jié)直腸癌患者的貧血程度，提高其治療效果，改善患者骨髓造血功能，值得臨床推廣應(yīng)用。

Objective To analyze the clinical effect of Compound Zaofan Pill in the treatment of anemia in colorectal cancer patients caused by FOLFOX4 regimen. Methods A retrospective study was conducted on 83 patients with colorectal cancer who developed anemia after receiving FOLFOX4 chemotherapy at the First Affiliated Hospital of the University of Science and Technology of China from January 2022 to June 2024. Patients were divided into two groups according to different methods of treating anemia. The control group (n = 41) was treated with recombinant human erythropoietin injection, the observation group (n = 42) was treated with Compound Zaofan Pill on the basis of the control group. The recent effects, adverse reactions, anemia status, and bone marrow hematopoietic function was compared between two groups. Results The recent improvement effect of anemia in the observation group (85.71%) was higher than that in the control group (58.54%). There was no statistically significant difference in the scores of the main and secondary symptoms between the two groups of patients before treatment (P > 0.05), but after treatment, the scores of the main and secondary symptoms in both groups of patients were significantly lower than before treatment (P < 0.05). After treatment, the scores of the main and secondary symptoms in the observation group were significantly lower than those in the control group (P < 0.05). Before treatment, there was no statistically significant difference (P > 0.05) in the objective indicators of prealbumin (PA), albumin (ALB), hemoglobin (Hb), white blood cells (WBC), red blood cells (RBC), platelet count (PLT), and CD3⁺, CD4⁺, CD4⁺/CD8⁺ between the two groups. However, after treatment, all objective indicators in the two groups were significantly reduced compared to before treatment (P < 0.05). After treatment, all indicators in the observation group were significantly higher than those in the control group (P < 0.05). The difference in adverse reactions between the two groups was not significant (P > 0.05). Conclusion Compound Zaofan Pill can improve the anemia level in patients with colorectal cancer caused by FOLFOX4 regimen, enhance its therapeutic effect, improve the patient's bone marrow hematopoietic function, and is worthy of clinical promotion and application.

R979.1

安徽省2023年度中央財(cái)政中醫(yī)藥事業(yè)傳承與發(fā)展專項(xiàng)資金項(xiàng)目（全國第七批全國名老中醫(yī)專家學(xué)術(shù)經(jīng)驗(yàn)繼承項(xiàng)目專項(xiàng)基金340000201280030000414-醫(yī)療服務(wù)能力提升補(bǔ)助資金）